On March 6, 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer reported that three abstracts submitted by the Company have been accepted for presentation as posters at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, CA, 5 – 10 April 2024 (Press release, Redx Pharma, MAR 6, 2024, View Source [SID1234640864]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One poster investigating Redx’s lead asset zelasudil (RXC007), a selective ROCK 2 inhibitor, currently in Phase
2a development for Idiopathic Pulmonary Fibrosis (IPF) which has shown promising preclinical efficacy in a range
of models, will be presented in collaboration with the Company’s research partner, the Garvan Institute of Medical
Research, Australia The data from preclinical models of pancreatic cancer shows the potential of zelasudil to
increase survival in mouse models of pancreatic ductal adenocarcinoma (PDAC), when used in combination with
current standard of care.

Redx will also present two posters on zamaporvint (RXC004) a potent and selective porcupine inhibitor targeting
Wnt-ligand dependent cancers, currently in Phase 2 development in hard-to-treat tumors. The first poster
highlights the potential to combine zamaporvint with MAPK pathway inhibitors in gastrointestinal cancer models
showing that co-inhibition of these pathways leads to synergistic effects in vitro and enhanced efficacy in vivo. The
second poster, entitled: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint
(RXC004) in patients with advanced solid tumors, will discuss final data from all the Phase 1 modules of the
programme. The abstract from this second poster will be available on 5 April 2024 at 3:00pm ET.

Richard Armer, Chief Scientific Officer, Redx Pharma commented: "To have three poster presentations at a
prestigious conference such as AACR (Free AACR Whitepaper) is a testament to the strength of our portfolio. With the potential to expand
the indications for zelasudil beyond IPF and interstitial lung diseases into fibrotic cancers such as pancreatic; and
the expansion of potential combination treatments with zamaporvint for hard-to-treat aggressive tumours, we are
optimistic about the utility of our drugs for a number of underserved patient populations."
Details of the poster presentations are as follows:

Zelasudil (RXC007)

Abstract Title: Combining Zelasudil, a small molecule ROCK2 inhibitor, with
chemotherapy or immunotherapy improves response in
preclinical models of Pancreatic cancer
Session Title: Tumor Microenvironment
Date/Time: Sunday Apr 7, 2024 1:30 PM – 5:00 PM
Location: Poster Section 29
Poster Board Number: 6
Published Abstract Number: 720
Zamaporvint (RXC004)

1) Abstract Title: Pre-clinical activity of the Wnt pathway inhibitor RXC004 in
combination with MAPK pathway inhibitors in GI cancer
models
Session Title: Application of Precision Medicine for Cancer Care
Date/Time: Sunday Apr 7, 2024 1:30 PM – 5:30 PM
Location: Poster Section 39
Poster Board Number: 12
Published Abstract Number: 944

2) Abstract Title: Final results of the first-in-human study of the porcupine
(PORCN) inhibitor zamaporvint (RXC004) in patients with
advanced solid tumors
Session Title: First-in-Human Phase I Clinical Trials 1
Date/Time: Monday Apr 8, 2024 1:30 PM – 5:30 PM
Location: Poster Section 48
Poster Board Number: 9
Published Abstract Number: CT101